Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment
Tuberculosis (TB) is an airborne bacterial infection caused by <i>Mycobacterium tuberculosis</i> (<i>M. tb</i>), resulting in approximately 1.3 million deaths in 2022 worldwide. Oral therapy with anti-TB drugs often fails to achieve therapeutic concentrations at the primary i...
Saved in:
Main Authors: | Druva Sarika Rongala (Author), Suyash M. Patil (Author), Nitesh K. Kunda (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clofazimine for the treatment of tuberculosis
by: Jacob A. M. Stadler, et al.
Published: (2023) -
Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis
by: Ahmad Z. Bahlool, et al.
Published: (2022) -
Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis: In vitro lung deposition and efficacy studies
by: Vishal Puri, et al.
Published: (2022) -
Development of L-Lysine-Loaded PLGA Microparticles as a Controlled Release System for Angiogenesis Enhancement
by: Nunzia Gallo, et al.
Published: (2023) -
Development of dry powder inhaler containing tadalafil-loaded PLGA nanoparticles
by: Jaleh Varshosaz, et al.
Published: (2017)